Vedaprofen NEW
| Price | $49 | $67 | $118 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-11-10 |
Product Details
| Product Name: Vedaprofen | CAS No.: 71109-09-6 |
| Purity: 99.24% | Supply Ability: 10g |
| Release date: 2025/11/10 |
Product Introduction
Bioactivity
| Name | Vedaprofen |
| Description | Vedaprofen (PM 150) inhibits COX-1 and reduces prostaglandin H2 synthesis with anti-inflammatory activities. Vedaprofen is an inhibitor of Escherichia coli sliding clamp with the IC50 of 222 μM and Ki of 131 μM. |
| In vitro | Vedaprofen blocks the activity of the E. coli DNA polymerase III β subunit, preventing DNA replication and repair[1]. Vedaprofen inhibits horse serum TxB2 and horse exudate PGE2 with IC50s of 9 ng/mL and 630 ng/mL, respectively[3]. |
| In vivo | In beagle dogs, the absorption of Vedaprofen (0.5 mg/kg; oral) was rapid (tmax 0.63 h) and almost complete (bioavailability 86%). The terminal half-lives after intravenous and oral administration, 16.8 and 12.7 h respectively, were of the same order of magnitude. Vedaprofen does not accumulate in plasma[2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | Ethanol : 10 mg/mL (35.41 mM), Sonication is recommended. DMF : 25 mg/mL (88.53 mM), Sonication is recommended. DMSO : 50 mg/mL (177.07 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (7.08 mM), Sonication is recommended. |
| Keywords | Vedaprofen | sliding clamp | serum TxB2 | ProstaglandinReceptor | Prostaglandin Receptor | PM-150 | PM150 | PGE2 | NSAID | nonsteroidal | Inhibitor | inhibit | exudate PGE2 | Escherichia coli | E. coli | Cyclooxygenase | COX-1 selective | COX-1 | COX | CERM-10202 | CERM10202 | Bacterial | anti-inflammatory drug |
| Inhibitors Related | Neomycin sulfate | Dehydroacetic acid sodium | Ampicillin sodium | Doxycycline (hyclate) | Methyl anthranilate | Kanamycin sulfate | Acetaminophen | Sulfamethoxazole sodium | Terbinafine hydrochloride | Doxycycline | Dimethyl sulfoxide | Ethyl acetoacetate |
| Related Compound Libraries | Pain-Related Compound Library | Bioactive Compound Library | Neuronal Signaling Compound Library | Membrane Protein-targeted Compound Library | ReFRAME Related Library | Inhibitor Library | Anti-Bacterial Compound Library | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $/ |
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY